复发/难治(R/R)外周T细胞淋巴瘤(PTCL)预后较差,治疗选择有限,通常没有持久的反应。然而,组蛋白去乙酰化酶(HDAC)抑制剂romidepsin的长期缓解已有报道,特别是在血管免疫母细胞性T细胞淋巴瘤(AITL)中。最近,tucidinostat,一种选择性抑制I类和II类HDAC的新型口服HDAC抑制剂,在中国和日本被批准用于R/RPTCL。我们介绍了AITL患者的情况,该患者在从罗米地辛转换为tucidinostat作为维持治疗后,胃肠道症状和与健康相关的生活质量得到了改善。Romidepsin和tucidinostat似乎具有不同的安全性;非血液毒性,如恶心,呕吐,便秘,与romidepsin相比,tucidinostat的厌食症和疲劳报告频率较低。这种情况表明,对于患有romidepsin严重胃肠道不良事件的PTCL患者,改用tucidinostat治疗可能是可行的选择。
Relapsed/refractory (R/R) peripheral T cell lymphoma (PTCL) has a poor prognosis, with limited treatment options and generally no durable response. However, long-term remission with the histone deacetylase (HDAC) inhibitor romidepsin has been reported, especially in angioimmunoblastic T cell lymphoma (AITL). Recently, tucidinostat, a novel oral HDAC inhibitor that selectively inhibits class I and class IIb HDACs, was approved for R/R PTCL in China and Japan. We present the
case of a patient with AITL whose gastrointestinal symptoms and health-related quality of life improved after switching from romidepsin to tucidinostat as maintenance therapy. Romidepsin and tucidinostat appear to have different safety profiles; non-haematological toxicities such as nausea, vomiting, constipation, anorexia and fatigue may be reported less frequently with tucidinostat than with romidepsin. This
case suggests that switching to tucidinostat therapy may be a viable option for patients with PTCL suffering from severe gastrointestinal adverse events with romidepsin.